Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis
Shuo Zhang, Zhen Chen, Puyu Shi, Songqing Fan, Yong He, Qiming Wang, Yixiang Li, Suresh S. Ramalingam, Taofeek K. Owonikoko, Shi‐Yong Sun
Abstract
Collectively, we suggest that DR4 downregulation is coupled to therapeutic efficacy of EGFR-targeted therapy and predicts improved prognosis, revealing a previously undiscovered connection between EGFR-targeted therapy and DR4 modulation.
Topics & Concepts
Cancer researchGene knockdownDownregulation and upregulationOsimertinibEpidermal growth factor receptorApoptosisBiologyTransactivationTargeted therapyLung cancerFlow cytometryMAPK/ERK pathwayCell cultureMolecular biologyChemistryCancerMedicineKinaseGene expressionPathologyCell biologyGeneErlotinibGeneticsBiochemistryCell death mechanisms and regulationCancer-related Molecular PathwaysLung Cancer Treatments and Mutations